Linda Schellhammer

Linda Schellhammer

Auto-generated profile, based on publicly available information

Linda Schellhammer

Institute of Laboratory Animal Science, University of Zurich, Schlieren, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MBMichal Beffinger
Michal Beffinger
LSLinda Schellhammer
Linda Schellhammer
BTBetül Taskoparan
Betül Taskoparan
SDSereina Deplazes
Sereina Deplazes
USUlisse Salazar
Ulisse Salazar
JBJohannes vom Berg
Johannes vom Berg
Glioblastoma remains a challenging indication for immunotherapy: the blood-brain barrier hampers accessibility for systemic treatments and the immunosuppressive microenvironment impedes immune attack. Intratumoral therapy with the proinflammatory cytokine interleukin-12 (IL-12) can revert immunosuppression but leakage into the circulation causes treatment-limiting toxicity. Here we engineer an IL-12Fc fusion cytokine with reduced binding to the neonatal Fc receptor FcRn. FcRn-silenced IL-12Fc avoids FcRn-mediated brain export, thus exhibits prolonged brain retention and reduced blood levels, which prevents toxicity. In murine glioblastoma, FcRn-silenced IL-12Fc induces more durable responses with negligible systemic cytokine exposure and boosts the efficacy of radio- and chemotherapy. It triggers anti-tumor responses independently of peripheral T cell influx or lymphopenia and leads to inflammatory polarization of the tumor microenvironment in patient-derived glioblastoma explants. FcRn-silencing of IL-12Fc may unlock the full potential of IL-12 for brain cancer therapy and could be further applied to containing the activity of other therapeutics targeting neurological diseases.

18 August 2021 in medRxiv
Verified
Preprint
Open access
PDF file
CJConstanze A. Jakwerth
Constanze A. Jakwerth
MFMartin Feuerherd
Martin Feuerherd
FGFerdinand M. Guerth
Ferdinand M. Guerth
MOMadlen Oelsner
Madlen Oelsner
LSLinda Schellhammer
Linda Schellhammer
ACAdam M. Chaker
Adam M. Chaker
Background: SARS-CoV2 has evolved to enter the host via the ACE2 receptor which is part of the Kinin-kallirein pathway. This complex pathway is only poorly understood in context of immune regulation but critical to control infection. This study examines SARS-CoV2 infection and epithelial mechanisms of the kinin-kallikrein system at the kinin B 2 receptor level in SARS-CoV-2 infection that is of direct translational relevance. Methods: From acute SARS-CoV-2-positive patients and -negative controls, transcriptomes of nasal brushings were analyzed. Primary airway epithelial cells (NHBEs) were infected with SARS-CoV-2 and treated with the approved B 2 R antagonist icatibant. SARS-CoV-2 RNA RT-qPCR, cytotoxicity assays, plaque assays and transcriptome analyses were performed. The treatment effect was further studied in a murine airway inflammation model in vivo . Results: Here, we report a broad and strong upregulation of kallikreins and the kinin B 2 receptor (B 2 R) in the nasal mucosa of acutely symptomatic SARS-CoV-2-positive patients. A B 2 R antagonist impeded SARS-CoV-2 replication and spread in NHBEs, as determined in plaque assays on Vero E6 cells. B 2 R antagonism reduced the expression of SARS-CoV-2 entry receptor ACE2 in vitro and in a murine airway inflammation model in vivo . In addition, it suppressed gene expression broadly, particularly genes involved in G-protein-coupled-receptor signaling and ion transport. Conclusions: In summary, this study provides evidence that treatment with B 2 R antagonists protects airway epithelial cells from SARS-CoV-2 by inhibiting its replication and spread, through the reduction of ACE2 levels and the interference with several cellular signaling processes. Future clinical studies need to shed light on the airway protection potential of approved B 2 R antagonists, like icatibant, in the treatment of early-stage COVID-19.